Japan iPS Patent Could Go To Germany’s Bayer, Office Says
This article was originally published in PharmAsia News
Executive Summary
The future of Japan's effort to promote research into induced pluripotent stem cells could hinge on a decision by the country's Patent Office. It found that Germany's Bayer had applied for several similar patents, including one for Kyoto University's method, three months before the Japanese researchers. If Bayer eventually is awarded the patent, observers expect Japanese patent rights to become so complicated the government's iPS research promotion policy could itself be affected. (Click here for more